miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Sunitinib is a multitargeting tyrosine kinase inhibitor used for metastatic renal cancer. There are no biomarkers that can predict sunitinib response. Such markers are needed to avoid administration of costly medication with side effects to patients who would not benefit from it. We compared global...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Ther
Main Authors: Khella, Heba W Z, Butz, Henriett, Ding, Qiang, Rotondo, Fabio, Evans, Kenneth R, Kupchak, Peter, Dharsee, Moyez, Latif, Ashraf, Pasic, Maria D, Lianidou, Evi, Bjarnason, Georg A, Yousef, George M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4817948/
https://ncbi.nlm.nih.gov/pubmed/26201448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2015.129
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados